UBS AG disclosed Essilor International (EPA:EI), boosting its price target to 141.00EUR earlier today
- Updated: February 11, 2017
Having a price of 109.15EUR, Essilor International (EPA:EI) traded 0.00% even on the day. With the last close up 0.00% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.06% over the same period. EI has recorded a 50-day average of 0.00EUR and a two hundred day average of 0.00EUR. Trade Volume held steady, with 0 shares of EI changing hands on par with the typical 0
Stating a potential upside of 0.29%, UBS AG bumped up the target of Essilor International (EPA:EI) to 141.00EUR
On Thursday February 09, 2017, UBS AG released a statement on Essilor International (EPA:EI) upped the target price from 0.00EUR to 141.00EUR that suggested an upside of 0.29%.
Recent Performance Chart
Essilor International has with a one year low of 0.00EUR and a one year high of 0.00EUR and has a market capitalization of 0 EUR.
General Company Details For Essilor International (EPA:EI)
Essilor International SA, formerly Essilor International Compagnie Generale D'Optique SA, is an ophthalmic optics company. The Company designs, manufactures and markets a range of lenses to improve and protect eyesight. It also develops and markets equipment for prescription laboratories, and instruments and services for eye care professionals. It operates through three segments: Lenses and Optical Instruments, Equipment, and Sunglasses & Readers. It is a North American provider of non-prescription reading glasses. It also sells non-prescription sunglasses. It has approximately 32 plants, over 490 prescription laboratories, edging facilities and local distribution centers, and over five research and development centers across the world. The Company designs, manufactures and customizes corrective lenses. The Company provides a range of lenses for correcting myopia, hyperopia, astigmatism and presbyopia. It operates through MyOptique Group.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.